Launch
FDA Adds Another Player in ALK-Positive Lung Cancer
The Brief
- The FDA granted accelerated approval to neladalkib, marketed as Nelkarmi, for previously treated advanced ALK-positive non-small cell lung cancer.
- Neladalkib is a third-generation ALK inhibitor and the seventh approved agent for this cancer type, according to MedPage Today.
Why it matters
It adds another targeted option for patients with ALK-positive lung cancer whose disease has progressed after earlier treatment. Accelerated approval rests on interim evidence, so confirmatory results will matter.
Who’s affected
- oncologists treating non-small cell lung cancer
- patients with previously treated ALK-positive advanced lung cancer
- #oncology
- #lung cancer
- #alk inhibitor
- #fda approval
- #targeted therapy
(MedPage Today) -- The FDA granted accelerated approval to the third-generation ALK inhibitor neladalkib (Nelkarmi) for previously treated advanced ALK-positive non-small cell lung cancer (NSCLC), making it the seventh approved agent in a crowded...